Sierra Oncology, Inc. announced it has established a DDR Advisory Committee composed of leading experts in this emerging field of cancer drug development. The DDR Advisory Committee will advise Sierra's management as it advances its DDR oriented development programs and seeks to maximize the potential clinical and commercial deployment of its drug candidates. Sierra Oncology's DDR Advisory Committee consists of: Eric J. Brown, PhD, Associate Professor of Cancer Biology at the Perelman School of Medicine of the University of Pennsylvania. Karlene Cimprich, PhD, Vice Chair and Professor of Chemical and Systems Biology at the Stanford University School of Medicine. Alan D. D'Andrea, MD, Fuller-American Cancer Society Professor of Radiation Oncology at Harvard Medical School and the Director of the Center for DNA Damage and Repair at the Dana-Farber Cancer Institute. Alan R. Eastman, PhD, Professor at the Geisel School of Medicine at Dartmouth and the founding Director of the Molecular Therapeutics Research Program of the Norris Cotton Cancer Center at Dartmouth. Michelle D. Garrett, PhD, Professor of Cancer Therapeutics in the School of Biosciences at the University of Kent and Visiting Professor of Cancer Therapeutics at the Institute of Cancer Research, London, UK. Thomas Helleday, PhD, The Torsten and Ragnar Söderberg Professor of Translational Medicine and Chemical Biology at Karolinska Institutet, Stockholm, Sweden. Leonard Post, PhD, Chief Scientific Officer of Vivace Therapeutics.